Evaluation of IL 12B Genetic Polymorphism (rs3213094)

ConditionPsoriasis

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-70

SponsorSouth Valley University

About this trial

Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus).

Pregnancy and lactation.

Patients currently undergoing any treatment other than Humira.

Patients with known genetic disorders affect immune system function.

Trial design

Design model

Parallel

Treatments tested in this trial

Humira
Drug
Assess the response of psoriasis and psoriatic arthritis to Humira and also Assessing the pharmacogenetic association between IL 12B genetic polymorphism (rs3213094) in psoriatic and psoriatic arthritis patients taking Humira.

Treatment groups

40 Participants

are divided into 2 treatment groups

Group A: Patients GroupActive comparator 1 intervention

Group B: Healthy GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

Treatment of Psoriasis and Psoriatic Arthritis

Treatment the patients whom suffering from Psoriasis and Psoriatic arthritis and Assessment of clinical improvement to Humira therapy according to: PASI score into PASI 50: means 50% reduction in PASI score - an acceptable measure of efficacy for secondary endpoints in psoriasis clinical trials PASI 75: means 75% reduction in PASI score - standard efficacy measure used in most psoriasis clinical studies1 PASI 90: means 90% reduction in PASI score (almost clear skin) PASI 100: means Completely clear skin.

Time frame

3 Months

Secondary outcomes

Evaluate the effect of treatment with Humira

Evaluate the effect of treatment with Humira therapy on the level of serum IL12B genetic polymorphism (rs3213094) on the Participants whom suffering from Psoriasis and Psoriatic arthritis.

Time frame

3 Months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

South Valley University

Lead sponsor

Source ClinicalTrials.gov

Apply now